Allogene Therapeutics To Lay Off 22% Of Its Workforce; Stock Down
Gene editing company, Allogene Therapeutics, Inc. (ALLO), Friday announced its decision to cut down its workforce by 22% in a move to focus on developing its blood cancer therapy.
Stay updated with breaking news from Allogene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Gene editing company, Allogene Therapeutics, Inc. (ALLO), Friday announced its decision to cut down its workforce by 22% in a move to focus on developing its blood cancer therapy.
SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, today presented long-term follow up... | June 5, 2023
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Focused
SOUTH SAN FRANCISCO, Calif., May 24, 2023 -- Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, today... | May 24, 2023
NEW YORK, Jan. 22, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers...